Active	Status	Sponsor type	Region	Phase	Filter
1 Active 21 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   - « April » « 2025 » M T W T F S S 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4   Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Amilo-5MER / Galmed, Hebrew University of Jerusalem
NCT05857215: A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects	Completed	1	55	Europe	amilo-5MER, Synthetic peptide consisting of 5 amino acids	Galmed Pharmaceuticals Ltd, Quotient Sciences	Inflammatory Disease	07/21	07/21

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Amilo-5MER / Galmed, Hebrew University of Jerusalem
NCT05857215: A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects	Completed	1	55	Europe	amilo-5MER, Synthetic peptide consisting of 5 amino acids	Galmed Pharmaceuticals Ltd, Quotient Sciences	Inflammatory Disease	07/21	07/21